

Multi-Targeted Nitrogen Bearing Heterocycle's for Alzheimer Disease

Kale Nikita Vitthal, Asst. Prof. Shubham L. Hange, Dr. Surwase K.P.
Kishori College of Pharmacy, Beed

Abstract: *Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, behavioral abnormalities, and impairment in daily activities. It is one of the leading causes of dementia among elderly individuals worldwide. The disease involves multiple pathological pathways such as amyloid-beta plaque formation, tau protein aggregation, oxidative stress, cholinergic dysfunction, mitochondrial damage, excitotoxicity, and neuroinflammation. Conventional therapies provide only symptomatic relief and fail to completely prevent disease progression.*

Modern medicinal chemistry focuses on the development of multi-target-directed ligands because Alzheimer's disease is a multifactorial disorder involving several biochemical pathways simultaneously. Nitrogen heterocyclic compounds are among the most important classes of compounds in medicinal chemistry due to their broad spectrum of biological activities, excellent pharmacokinetic properties, and ability to interact with multiple biological targets.

Nitrogen heterocycles contain one or more nitrogen atoms incorporated into cyclic ring structures. These compounds exhibit antioxidant, anti-inflammatory, antimicrobial, anticancer, anticonvulsant, and neuroprotective properties. In Alzheimer's disease therapy, nitrogen heterocyclic compounds have shown promising effects through acetylcholinesterase inhibition, prevention of amyloid aggregation, reduction of oxidative stress, modulation of neurotransmitter levels, and neuroprotection.

This project discusses the role of multi-targeted nitrogen heterocycles in Alzheimer's disease treatment. The report includes detailed information regarding Alzheimer's disease pathology, causes, symptoms, nitrogen heterocyclic chemistry, classification, synthesis, drug design strategies, mechanism of action, biological evaluation, pharmacological activities, advantages, limitations, and future scope..

Keywords: *Alzheimer's disease*

I. INTRODUCTION

In the universe, aging is a common biological mechanism that occurs in all living species. In humans, the process of aging is divided into two categories such as programmed and error or damage theories. The programmed theories emphasize that aging involves the prolongation of the sequential switching on and off of certain genes essential to follow a biological schedule, which regulates the growth and development of adolescence. This theory mainly affects the entire system responsible for repair, maintenance and defines mechanism due to the changes in gene expression. The error or damage theories of aging involves the ecological threats to living organisms which induces the cause of aging process in humans [1]. Moreover, aging is responsible for various types of cancer, cardiac diseases, inflammation and neurological disorder like Alzheimer's disease (AD). Among that AD is the most common form of dementia which affects most of the elderly people. AD is characterized by the aggregation of extracellular amyloid β -protein ($A\beta$) that primarily occur in a filamentous form known as plaques and intracellular hyperphosphorylated tau protein known as neurofibrillary tangles [2]. These changes in the brain cause synaptic loss and dysfunction of neurons leads to reduction in glucose metabolism and shrinkage of grey matter. Also, the formation of plaques affects communication between neurons at synapses and intracellular phosphorylated tau tangles blocks the nutrient transportation and other essential nutrients leads to cell death [3,4]. The symptoms of AD are cognitive dysfunction, issues in planning or problem-solving tasks, poor judgement, depression, confusion and behavioural changes which can disrupt the person's daily



activities [5]. To date, the development of therapeutic drugs against AD is the promising strategy due to the poor diffusion of drugs across the blood brain barrier (BBB). Furthermore, there is a need for development of novel, safe, and efficient therapies for this neurodegenerative disease. Recent studies have focused on the development of novel drugs from natural sources to treat various disorders, including AD [6]. This review highlights the use of heterocyclic compounds in the treatment of AD.

Phytopharmacology Pathology of AD

The pathology of AD involves the formation of senile plaques due to the aggregation of amyloid beta ($A\beta$) peptides that induces the reactive oxygen species (ROS). Then the diminution of cholinergic neurons increased the activity of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) results in cognitive losses [7]. Additionally, a few other reports showed that an inflammatory mechanism is also responsible for the pathology of AD. Histopathological studies showed that the presence of $A\beta$ peptides in AD patients is correlated with groups of activated microglia cells and inflammatory proteins such as complement proteins, acute-phase proteins and anti-inflammatory cytokines [8]. Some studies indicated that the genetic variation of cytokines, particularly over expression of interleukin-1 and acute phase proteins triggers the cause of AD [9]. Several studies reported that elevated serum level of high sensitivity C-reactive protein (hs-CRP) that are found in extracellular plaques and tangles, acute phase reactant like α 1-antichymotrypsin and interleukin-6 are associated with the cause of AD [10-12]. Based on the epidemiologic surveys suggested that the prolonged use of anti inflammatory drugs may prevent or slow down the progression of AD [13,14]. The formation of amyloid peptides by APP (amyloid precursor protein) pathway is mainly involved in the pathology of AD [15]. The APP hypothesis involves the cleavage of α or β -secretase which releases APP. Although the products released by cleavage of α secretase are considered as nontoxic, β -secretase involves the amyloidogenic and non-amyloidogenic division of APP pathway. Further the cleavage of β -secretase involves the formation of C terminal APP (C-APP) by γ -secretase, based on the cleavage site, variable length of $A\beta$ peptides are formed from the plasma membrane. Among these peptides, $A\beta$ 42 is considered as the main pathological cause of AD [16,17]. The oxidative stress is also a major impact in the pathogenesis of AD. The formation of reactive oxygen species (ROS) or free radicals such as hydrogen peroxide (H_2O_2), hydroxyl (OH) and superoxide (O_2) stimulate oxidative damage which leads to DNA strand breaks, destruction of nucleic acids and sugars in the cell membrane and finally induces cell death [18,19]. Based on the epidemiologic studies, it was indicated that Apolipoprotein E (ApoE) genotype is also responsible for the pathology of AD. Lipid metabolism is regulated by three ApoE isoforms such as apoE2, apoE3, and apoE4 which are encoded by different alleles (ϵ 2, ϵ 3, ϵ 4). In US, based on the clinical studies showed that ϵ 4 allele is responsible for 50% of AD and 95% of AD cases are due to the variation of ϵ 2 allele in the gene encoding this protein. Additionally, several studies suggested that the fragments of ApoE are also responsible for the formation of plaques and tangles [20]. Based on these pathologies, the development of therapeutic drugs with less side effects against AD are the major task of this period. Although few drugs are approved by the U.S. Food and Drug Administration (FDA) for treating cognitive disorder like AD, but the efficiency varies among individuals [21].






Figure 1.1 Phytopharmacology Pathology of AD

Aim and Objectives

The main aim of this project is to study the role of multi-targeted nitrogen heterocyclic compounds in the treatment and management of Alzheimer's disease.

To study the causes, symptoms, and pathophysiology of Alzheimer's disease. To understand the importance of nitrogen heterocyclic compounds in medicinal chemistry. To classify different types of nitrogen heterocyclic compounds used in drug discovery. To study the concept of multi-target-directed ligands for Alzheimer's disease treatment. To evaluate the mechanism of action of nitrogen heterocycles in neuroprotection. To study various drug design strategies used for developing anti-Alzheimer agents. To understand the synthesis methods of nitrogen heterocyclic compounds. To study characterization techniques such as IR, NMR, Mass Spectroscopy, and UV spectroscopy. To evaluate the biological and pharmacological activities of synthesized compounds. To analyze the advantages and limitations of multi-targeted nitrogen heterocyclic compounds. To explore the future scope of nitrogen heterocycles in Alzheimer's disease therapy. To understand the importance of developing safer and more effective drugs for neurodegenerative disorders.

Literature Review

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by memory loss, cognitive dysfunction, behavioral abnormalities, and neuronal degeneration. The disease mainly affects elderly individuals and is considered one of the leading causes of dementia worldwide. Several pathological mechanisms including amyloid-beta plaque formation, tau protein aggregation, oxidative stress, cholinergic dysfunction, neuroinflammation, and mitochondrial damage are responsible for the progression of Alzheimer's disease.

According to Saravana Priya Palaniappan, currently available drugs for Alzheimer's disease mainly provide symptomatic relief and prolonged use may produce adverse side effects. Therefore, the development of novel therapeutic agents from natural and synthetic heterocyclic compounds has become an important area of research.

The pathology of Alzheimer's disease involves accumulation of amyloid-beta peptides, oxidative stress, activation of acetylcholinesterase enzymes, and inflammatory mediators. Reactive oxygen species generated during oxidative stress



damage neuronal cells and contribute to neurodegeneration. Studies have also shown that inflammatory cytokines such as interleukin-1 and C-reactive proteins are associated with Alzheimer's disease progression.

Several researchers have reported that acetylcholinesterase inhibitors such as tacrine, donepezil, galantamine, and rivastigmine improve cognitive function by increasing acetylcholine concentration in the brain. However, these drugs show limitations including hepatotoxicity, gastrointestinal disturbances, and incomplete disease control.

Nitrogen heterocyclic compounds have attracted significant attention in medicinal chemistry because of their broad spectrum pharmacological activities. Heterocyclic compounds contain one or more heteroatoms such as nitrogen, oxygen, or sulfur within the ring structure. These compounds exhibit excellent biological properties including antioxidant, anti-inflammatory, antimicrobial, anticancer, and neuroprotective activities.

Researchers have focused on nitrogen-containing heterocycles such as pyridine, pyrimidine, imidazole, pyrazole, quinoline, indole, triazole, and benzimidazole because these compounds demonstrate strong interaction with biological targets involved in Alzheimer's disease. Nitrogen heterocycles are capable of crossing the blood-brain barrier and interacting with acetylcholinesterase enzymes, amyloid-beta proteins, and inflammatory mediators.

Studies reported that triazole, pyrazole, and benzimidazole derivatives exhibit significant antioxidant and neuroprotective activities. These compounds reduce oxidative stress and protect neuronal cells from degeneration. Benzofuran and quinoline derivatives also show anti-amyloid and anti-inflammatory activities useful for Alzheimer's disease treatment.

Modern drug discovery approaches focus on multi-target-directed ligands because Alzheimer's disease involves multiple biochemical pathways. Multi-targeted nitrogen heterocyclic compounds can simultaneously inhibit acetylcholinesterase enzymes, reduce oxidative stress, prevent amyloid aggregation, and suppress neuroinflammation. This multi-target approach improves therapeutic efficacy and reduces drug resistance.

Several synthetic methods have been developed for the preparation of nitrogen heterocycles including cyclization reactions, condensation reactions, microwave-assisted synthesis, and green chemistry approaches. Characterization of synthesized compounds is carried out using techniques such as IR spectroscopy, NMR spectroscopy, mass spectrometry, and chromatography. These analytical methods confirm the purity and molecular structure of heterocyclic compounds.

Biological evaluation studies indicate that nitrogen heterocyclic compounds possess promising anti-Alzheimer activity with reduced toxicity. In vitro and in vivo studies have demonstrated their ability to improve memory, reduce neuronal damage, and enhance cognitive functions. Therefore, nitrogen heterocycles are considered promising candidates for future Alzheimer's disease therapy.

In conclusion, literature studies suggest that multi-targeted nitrogen heterocyclic compounds represent an important and emerging area in Alzheimer's disease treatment. Their broad pharmacological profile, ability to act on multiple disease pathways, and neuroprotective potential make them promising therapeutic agents for future anti-Alzheimer drug development.

It is one of the major causes of dementia among elderly individuals worldwide. The prevalence of Alzheimer's disease is continuously increasing due to aging populations and changing lifestyles. Studies indicate that millions of new cases are reported every year globally, making Alzheimer's disease a major public health concern.

The pathology of Alzheimer's disease involves several complex biochemical and cellular mechanisms. Major pathological features include amyloid-beta plaque formation, neurofibrillary tangles, oxidative stress, mitochondrial dysfunction, neuroinflammation, and cholinergic neuronal degeneration. Amyloid-beta peptides accumulate outside neurons and form plaques that disrupt neuronal communication. Similarly, abnormal phosphorylation of tau proteins leads to formation of neurofibrillary tangles inside neurons, resulting in neuronal death and cognitive impairment.

Researchers have proposed different hypotheses to explain Alzheimer's disease progression. The cholinergic hypothesis suggests that deficiency of acetylcholine neurotransmitter contributes significantly to memory loss and cognitive dysfunction. Acetylcholinesterase inhibitors such as donepezil, rivastigmine, tacrine, and galantamine are



used to increase acetylcholine levels in the brain and improve memory functions. However, these drugs mainly provide symptomatic relief and do not completely prevent disease progression.

Memantine, an NMDA receptor antagonist, is another approved drug used for moderate to severe Alzheimer's disease. It reduces glutamate-induced excitotoxicity and protects neurons from damage. Although currently available therapies improve cognitive functions temporarily, they are associated with limitations such as hepatotoxicity, gastrointestinal disturbances, dizziness, headache, and incomplete therapeutic efficacy.

Oxidative stress plays a major role in Alzheimer's disease pathology. Excess production of reactive oxygen species damages proteins, lipids, enzymes, mitochondrial membranes, and DNA within neuronal cells. Researchers reported that antioxidants such as vitamin E, carotenoids, curcumin, and synthetic antioxidant compounds reduce oxidative stress and protect neuronal tissues from degeneration.

Neuroinflammation is another important pathological mechanism associated with Alzheimer's disease. Activation of microglial cells and inflammatory cytokines such as IL-1 β , TNF- α , and IFN- γ promotes neuronal injury and accelerates neurodegeneration. Recent therapeutic approaches aim to suppress neuroinflammation and improve neuronal survival.

Nitrogen heterocyclic compounds have gained significant importance in medicinal chemistry due to their broad spectrum biological activities and excellent pharmacological properties. These compounds contain one or more nitrogen atoms incorporated within cyclic ring systems. Nitrogen heterocycles exhibit antioxidant, anti-inflammatory, antimicrobial, anticancer, anticonvulsant, and neuroprotective activities. Their structural diversity and ability to interact with multiple biological targets make them promising therapeutic agents for Alzheimer's disease treatment.

Several classes of nitrogen heterocyclic compounds including pyridine, pyrimidine, quinoline, indole, pyrazole, imidazole, triazole, piperidine, and benzimidazole derivatives have been investigated for anti-Alzheimer activity. These compounds exhibit multiple mechanisms of action such as acetylcholinesterase inhibition, antioxidant activity, anti-inflammatory effects, inhibition of amyloid-beta aggregation, metal chelation, and neuroprotection.

Modern medicinal chemistry focuses on multi-target-directed ligands because Alzheimer's disease involves several interconnected pathological pathways. Multi-target compounds can simultaneously inhibit cholinesterase enzymes, reduce oxidative stress, suppress neuroinflammation, and prevent amyloid plaque formation. According to recent studies, multi-target-directed nitrogen heterocyclic compounds provide improved therapeutic efficacy and better disease management compared to single-target drugs.

Research studies also highlight the importance of tau protein inhibition in Alzheimer's disease therapy. Hyperphosphorylation of tau proteins results in neurofibrillary tangle formation and neuronal degeneration. Glycogen synthase kinase-3 inhibitors, microtubule stabilizers, and tau aggregation inhibitors are being investigated as potential therapeutic agents.

Various immunotherapeutic approaches are also under clinical investigation for Alzheimer's disease treatment. Anti-amyloid monoclonal antibodies such as Aducanumab, Gantenerumab, Solanezumab, and BAN2401 target amyloid-beta plaques and reduce plaque accumulation in the brain. Among these, Aducanumab has shown promising effects in reducing amyloid burden and slowing cognitive decline in clinical studies.

Herbal medicines and natural products are also being explored for Alzheimer's disease therapy because of their safety and neuroprotective properties. Plant-derived compounds such as curcumin, ginsenosides, berberine, crocin, withanolides, and bacosides demonstrate antioxidant, anti-inflammatory, anti-amyloid, and cholinesterase inhibitory activities. Studies suggest that these compounds may improve memory and cognitive functions in Alzheimer's disease patients.

Recent research focuses on advanced therapeutic strategies such as nanotechnology- based drug delivery systems, artificial intelligence-assisted drug design, molecular docking studies, and gut microbiota modulation. Novel compounds like sodium oligomannate (GV- 971) have shown promising clinical results by reducing neuroinflammation and remodeling gut microbiota.

In conclusion, literature studies indicate that Alzheimer's disease is a multifactorial disorder requiring multi-target therapeutic approaches. Nitrogen heterocyclic compounds represent an important class of molecules due to their diverse



pharmacological activities and ability to act on multiple disease pathways simultaneously. Continued research in medicinal chemistry, biological evaluation, computational drug design, and clinical studies may lead to development of safer and more effective anti-Alzheimer agents in the future.

According to Christina Rahm, Alzheimer's disease remains one of the major challenges in modern medicine because currently available therapies only provide symptomatic relief and are unable to completely cure the disease. Pharmacological treatment mainly includes acetylcholinesterase inhibitors and NMDA receptor antagonists that improve neurotransmission and temporarily reduce cognitive symptoms. However, these therapies are associated with limitations such as poor efficacy, side effects, and inability to stop neuronal degeneration.

Several researchers have emphasized the importance of the cholinergic hypothesis in Alzheimer's disease pathology. According to this hypothesis, degeneration of cholinergic neurons and reduction in acetylcholine levels lead to memory impairment and cognitive dysfunction. Drugs such as donepezil, galantamine, tacrine, and rivastigmine inhibit acetylcholinesterase enzymes and increase acetylcholine concentration in the brain. Although these drugs improve memory temporarily, they do not completely prevent disease progression.

Oxidative stress is another important pathological mechanism involved in Alzheimer's disease. Excessive generation of reactive oxygen species damages neuronal proteins, lipids, enzymes, mitochondrial membranes, and DNA. Oxidative damage ultimately results in neuronal death and cognitive decline. Studies indicate that antioxidant compounds can reduce oxidative stress and protect neuronal tissues from degeneration. Therefore, modern research focuses on developing compounds with strong antioxidant and neuroprotective activities.

Neuroinflammation also contributes significantly to Alzheimer's disease progression. Activation of microglial cells and inflammatory cytokines leads to neuronal injury and synaptic dysfunction. Inflammatory mediators such as TNF- α , IL-1 β , and interferons promote neurodegeneration and worsen cognitive impairment. Recent therapeutic approaches aim to suppress inflammatory pathways and improve neuronal survival.

Research studies suggest that regular physical exercise improves cerebral blood flow, hippocampal volume, and cognitive performance. Exercise increases oxygen supply to brain tissues, enhances neuronal plasticity, and reduces the risk of dementia. Studies by Peter Scheltens and co-workers demonstrated that individuals performing regular exercise show improved cognitive functions and reduced risk of Alzheimer's disease compared to sedentary individuals.

Nitrogen heterocyclic compounds have attracted considerable attention in medicinal chemistry because of their broad spectrum pharmacological activities and ability to interact with multiple biological targets. Nitrogen heterocycles contain one or more nitrogen atoms within cyclic ring systems and are widely present in pharmaceutical drugs and natural products. These compounds exhibit antioxidant, anti-inflammatory, antimicrobial, anticonvulsant, anticancer, and neuroprotective properties.

Researchers have investigated various nitrogen heterocyclic scaffolds including pyridine, pyrimidine, quinoline, indole, triazole, pyrazole, benzimidazole, piperidine, and imidazole derivatives for anti-Alzheimer activity. These compounds demonstrate multiple mechanisms of action such as acetylcholinesterase inhibition, butyrylcholinesterase inhibition, anti-amyloid activity, metal chelation, antioxidant effects, and neuroprotection. Their ability to cross the blood-brain barrier makes them promising therapeutic agents for neurodegenerative disorders.

Modern medicinal chemistry focuses on the development of multi-target-directed ligands because Alzheimer's disease involves several interconnected biochemical pathways. Multi-target compounds are capable of simultaneously inhibiting acetylcholinesterase enzymes, reducing oxidative stress, preventing amyloid-beta aggregation, and suppressing neuroinflammation. This approach provides improved therapeutic efficacy compared to single-target drugs. Several synthetic methods have been developed for preparation of nitrogen heterocyclic compounds including cyclization reactions, condensation reactions, microwave-assisted synthesis, and green chemistry approaches. Characterization of synthesized compounds is carried out using techniques such as IR spectroscopy, NMR spectroscopy, mass spectrometry, UV spectroscopy, and chromatography. These analytical techniques confirm the molecular structure and purity of synthesized compounds.



Biological evaluation studies indicate that nitrogen heterocyclic compounds possess promising anti-Alzheimer activity with reduced toxicity. In vitro and in vivo studies demonstrate improvement in memory, reduction of oxidative damage, inhibition of cholinesterase enzymes, and protection of neuronal cells. Researchers continue to investigate novel heterocyclic molecules for development of safer and more effective anti-Alzheimer therapeutic agents.

Recent studies also focus on advanced therapeutic strategies such as artificial intelligence-assisted drug design, nanotechnology-based drug delivery systems, molecular docking studies, and biomarker-based diagnosis. These technologies may improve drug targeting, enhance blood-brain barrier penetration, and reduce adverse effects associated with conventional therapies.

In conclusion, literature studies reveal that Alzheimer's disease is a multifactorial disorder requiring multi-target therapeutic approaches. Nitrogen heterocyclic compounds represent an important class of molecules due to their diverse pharmacological activities, structural flexibility, and ability to act on multiple disease pathways simultaneously. Continued research in medicinal chemistry, biological evaluation, computational drug design, and clinical studies may lead to the development of safer and more effective anti-Alzheimer drugs in the future.

Alzheimer's Disease

Alzheimer's disease is a chronic neurodegenerative disorder characterized by gradual loss of neurons and decline in cognitive functions. It is the leading cause of dementia among older adults.

Characteristics of Alzheimer's Disease

- Memory loss
- Difficulty in thinking and reasoning
- Behavioral changes
- Language problems
- Confusion and disorientation
- Loss of judgment



Alzheimer's disease




Figure 1.2 Alzheimer's disease

Types of Alzheimer's Disease

Alzheimer's disease is classified into different types based on age of onset, genetic factors, and disease progression.

1. Early-Onset Alzheimer's Disease

This type occurs before the age of 65 years. It is less common and may develop in individuals between 30 and 60 years of age.

Characteristics

- Rapid progression of symptoms
- Strong genetic association
- Memory loss and behavioral changes at younger age Causes
- Mutations in APP, PSEN1, and PSEN2 genes
- Familial inheritance patterns

2. Late-Onset Alzheimer's Disease

This is the most common form of Alzheimer's disease and usually occurs after the age of 65 years.

Characteristics

- Slow progression
- Gradual memory decline
- Cognitive impairment in elderly individuals Risk Factors
- Aging
- Lifestyle factors
- Environmental influences



- APOE-e4 gene

3. Familial Alzheimer's Disease

Familial Alzheimer's disease is an inherited form caused by genetic mutations passed from parents to offspring.

Characteristics

- Strong family history
- Earlier onset of symptoms
- Rapid disease progression Genetic Mutations Involved
- APP gene
- Presenilin-1 (PSEN1)
- Presenilin-2 (PSEN2)

4. Sporadic Alzheimer's Disease

This is the most common non-inherited form of Alzheimer's disease. It develops due to multiple factors rather than direct genetic inheritance.

Characteristics

- No clear family history
- Usually develops after 65 years
- Influenced by aging and lifestyle Risk Factors
- Hypertension
- Diabetes
- Obesity
- Smoking
- Lack of physical activity

5. Mixed Dementia

Mixed dementia occurs when Alzheimer's disease is associated with other forms of dementia such as vascular dementia or Lewy body dementia.

Characteristics

- Combination of symptoms from multiple dementias
- Memory loss with movement disorders
- Severe cognitive decline Causes
- Reduced blood supply to brain
- Amyloid plaque formation
- Neurodegeneration

6. Posterior Cortical Atrophy (PCA)

Posterior cortical atrophy is a rare variant of Alzheimer's disease affecting the posterior region of the brain.

Characteristics

- Visual disturbances
- Difficulty recognizing objects
- Problems with reading and coordination Affected Areas
- Occipital cortex
- Parietal cortex



7. Logopenic Variant Primary Progressive Aphasia (lvPPA)

This type mainly affects speech and language functions. Characteristics

- Difficulty finding words
- Slow speech
- Impaired communication abilities Brain Regions Affected
- Left temporal lobe
- Parietal regions

8. Atypical Alzheimer's Disease

Atypical Alzheimer's disease presents symptoms different from classical memory loss. Characteristics

- Early behavioral changes
- Visual or language impairment
- Difficulty in movement and coordination Importance
- Difficult to diagnose in early stages
- Requires advanced neurological examination

9. Mild Cognitive Impairment Due to Alzheimer's Disease

This is an early stage between normal aging and severe Alzheimer's disease. Characteristics

- Mild memory loss
- Difficulty concentrating
- Preserved daily activities Importance
- Early diagnosis may slow progression
- Useful for preventive therapy

10. Secondary Alzheimer's Disease

This form develops due to other medical conditions or external factors. Causes

- Brain injury
- Stroke
- Chronic infections
- Metabolic disorders Characteristics
- Cognitive decline associated with underlying disease
- Progressive neuronal damage



Causes and Risk Factors




Figure 1.3 Causes and Risk Factors

Several factors contribute to the development of Alzheimer's disease.

1. Age

Increasing age is the major risk factor.

2. Genetics

Mutations in APP, PSEN1, and PSEN2 genes increase disease risk.

3. Oxidative Stress

Free radicals damage neurons and brain tissues.

4. Amyloid Plaques

Accumulation of amyloid-beta protein forms plaques in the brain.

5. Neurofibrillary Tangles

Tau protein abnormalities lead to tangles inside neurons.

6. Inflammation

Chronic neuroinflammation damages brain cells.

7. Lifestyle Factors

Smoking, obesity, diabetes, hypertension, and lack of exercise contribute to disease progression.



Symptoms of Alzheimer's Disease Symptoms develop gradually and worsen over time. Early Symptoms

- Forgetfulness
- Difficulty remembering names
- Mood changes
- Mild confusion

Moderate Symptoms

- Difficulty in communication
- Trouble performing daily tasks
- Personality changes
- Poor judgment

Severe Symptoms

- Complete memory loss
- Inability to recognize family members
- Difficulty swallowing
- Loss of physical functions

Pathophysiology

The pathophysiology of Alzheimer's disease involves multiple biochemical and cellular mechanisms.

Amyloid Cascade Hypothesis

Amyloid-beta peptides accumulate in the brain and form plaques that damage neurons.

Tau Hypothesis

Tau proteins become hyperphosphorylated and form neurofibrillary tangles.

Cholinergic Hypothesis

Loss of cholinergic neurons reduces acetylcholine levels leading to memory impairment.

Oxidative Stress

Reactive oxygen species damage lipids, proteins, and DNA.

Neuroinflammation

Activation of microglia releases inflammatory mediators causing neuronal injury.

Nitrogen Heterocycles

Nitrogen heterocycles are cyclic organic compounds containing one or more nitrogen atoms in the ring structure.

These compounds are highly important in medicinal chemistry because they show broad biological activities and good pharmacokinetic properties.



Common Nitrogen Heterocyclic Scaffolds		
Scaffold Type	Role in AD Treatment	Example / Reference
Piperidine	Core of FDA-approved AChE inhibitors.	Donepezil
Pyridine	Enhances bioavailability and acts as a metal chelate.	Pyclen derivatives
Pyrimidine	Inhibits amyloid aggregation and stabilizes tau.	Recent clinical trial candidates
Benzimidazole	Multi-targeted potential for neuroprotection.	Experimental MTDLs

Figure 1.4 Common Nitrogen Heterocyclic Scaffolds



Importance in Drug Discovery




Figure 1.5 Importance in Drug Discovery

- Enhanced biological activity
- Improved drug stability
- Better solubility
- Ability to cross the blood-brain barrier



Applications of Nitrogen Heterocyclic Compounds

Nitrogen heterocyclic compounds are organic compounds that contain nitrogen atoms in a ring structure. These compounds are widely used in medicinal chemistry because they show strong biological activities and are present in many pharmaceutical drugs. Their applications in different therapeutic areas are explained below in detail.




Figure 1.6 Applications of Nitrogen Heterocyclic Compounds

1. Anticancer Drugs

Nitrogen heterocycles play an important role in the development of anticancer agents. Many clinically used chemotherapy drugs contain pyridine, pyrimidine, quinoline, indole, imidazole, or triazole rings. These compounds act by inhibiting DNA synthesis, blocking enzymes, or stopping the growth of cancer cells.

Mechanism of Action

- Inhibit DNA replication in cancer cells
- Block cell division (mitosis)
- Inhibit protein kinases and enzymes
- Induce apoptosis (programmed cell death)

Important Nitrogen Heterocyclic Anticancer Drugs

1. Imatinib

- Contains a pyrimidine ring
- Used for chronic myeloid leukemia (CML)
- Inhibits tyrosine kinase enzyme



2. Erlotinib
 - Quinazoline derivative
 - Used in lung cancer treatment
 - Blocks epidermal growth factor receptor (EGFR)
3. Temozolomide
 - Imidazotetrazine derivative
 - Used for brain tumors and glioblastoma
 - Causes DNA damage in tumor cells
4. Methotrexate
 - Pteridine heterocycle

- Used in leukemia and breast cancer
- Inhibits folic acid metabolism

Advantages

- High biological activity
- Selective action on tumor cells
- Better drug-target interaction

Limitations

- Drug resistance
- Toxic side effects
- Damage to healthy cells

2. Antimicrobial Agents

Nitrogen heterocyclic compounds are widely used as antibacterial, antifungal, antiviral, and antiparasitic agents. Their ring systems help in interacting with microbial enzymes and proteins.


Mechanism of Action

- Inhibit bacterial cell wall synthesis
- Block nucleic acid synthesis
- Disrupt protein synthesis
- Damage microbial membranes




Important Antimicrobial Nitrogen Heterocycles

1. Metronidazole



metronidazole


- Nitroimidazole derivative
- Effective against anaerobic bacteria and protozoa



Ciprofloxacin



2. Ciprofloxacin




ketoconazole

- Fluoroquinolone compound
- Used against urinary tract and respiratory infections
- Inhibits bacterial DNA gyrase enzyme

3. Ketoconazole

- Imidazole antifungal agent
- Used in fungal infections
- Inhibits fungal sterol synthesis

4. Isoniazid



Isoniazid

- Pyridine derivative
- Used in tuberculosis treatment

Advantages

- Broad-spectrum activity
- High potency
- Effective against resistant strains

Limitations

- Antibiotic resistance
- Allergic reactions
- Gastrointestinal side effects

3. Anti-inflammatory Drugs

Nitrogen-containing heterocycles are used in anti-inflammatory medicines because they reduce pain, swelling, and inflammation by inhibiting inflammatory mediators.

Mechanism of Action

- Inhibit cyclooxygenase (COX) enzymes
- Reduce prostaglandin synthesis
- Suppress inflammatory cytokines

Important Drugs

1. Celecoxib

- Pyrazole-containing drug
- Selective COX-2 inhibitor
- Used in arthritis and joint pain

2. Indomethacin

- Indole derivative
- Used for rheumatoid arthritis and inflammation

3. Piroxicam

- Benzothiazine derivative
- Long-acting anti-inflammatory drug

Advantages

- Effective pain relief
- Reduced inflammation
- Better patient comfort

Limitations

- Gastric irritation
- Kidney toxicity
- Cardiovascular risks

4. Antidepressants

Many antidepressant drugs contain nitrogen heterocyclic structures because these rings improve interaction with neurotransmitter receptors in the brain.

Mechanism of Action

- Increase serotonin and norepinephrine levels
- Block neurotransmitter reuptake
- Improve mood and emotional stability

Important Antidepressant Drugs



1. Fluoxetine
 - Contains heterocyclic structure
 - Selective serotonin reuptake inhibitor (SSRI)
 - Used in depression and anxiety disorders
2. Imipramine
 - Dibenzazepine heterocycle
 - Tricyclic antidepressant
3. Alprazolam
 - Triazolobenzodiazepine derivative
 - Used for anxiety and panic disorders
4. Trazodone
 - Triazolopyridine derivative
 - Used for depression and insomnia

Advantages

- Improve mental health
- Reduce anxiety and stress
- Better sleep quality

Limitations

- Drowsiness
- Dependence in some drugs
- Delayed therapeutic effect

5. Neuroprotective Agents

Nitrogen heterocyclic compounds are important in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and epilepsy. These compounds protect neurons from damage and improve brain function.

Mechanism of Action

- Prevent oxidative stress
- Inhibit acetylcholinesterase enzyme
- Improve neurotransmitter function
- Reduce neuronal degeneration

Important Neuroprotective Drugs

1. Donepezil
 - Piperidine derivative
 - Used in Alzheimer's disease
 - Enhances acetylcholine levels in the brain
2. Rivastigmine
 - Carbamate-containing heterocycle
 - Used in dementia treatment
3. Levodopa
 - Used in Parkinson's disease
 - Increases dopamine levels
4. Memantine
 - Adamantane derivative containing nitrogen
 - Protects neurons from glutamate toxicity

Advantages

- Improve memory and cognition
- Slow disease progression



- Enhance quality of life
 - Limitations
 - Temporary symptom relief
 - Side effects like nausea and dizziness
 - Limited cure for neurodegenerative diseases
- Classification of Nitrogen Heterocycles




Figure 1.7 Classification of Nitrogen Heterocycles

Nitrogen heterocycles are classified according to ring size and number of nitrogen atoms.



Five-Membered Rings




Figure 1.8 Five-Membered Rings

Pyrrole

Contains one nitrogen atom.

Imidazole

Contains two nitrogen atoms.

Pyrazole

Widely used in pharmaceuticals.

Six-Membered Rings Pyridine

Important scaffold in medicinal chemistry.

Pyrimidine

Present in many therapeutic drugs.

Piperidine

Commonly used in CNS-active drugs.

Fused Heterocycles Quinoline

Exhibits antioxidant and neuroprotective activity.

Indole

Found in several natural products.

Benzimidazole

Shows antimicrobial and CNS activities.



Multi-Target Drug Approach

Alzheimer's disease involves multiple pathological pathways. Therefore, drugs targeting only one mechanism are less effective.

The multi-target approach focuses on designing compounds capable of acting on multiple targets simultaneously.

Advantages of Multi-Target Drugs

- Improved therapeutic efficacy
- Reduced drug resistance
- Better patient compliance
- Lower side effects
- Simultaneous treatment of multiple pathways

Targets in Alzheimer's Disease

- Acetylcholinesterase enzyme
- Butyrylcholinesterase enzyme
- Amyloid-beta aggregation
- Oxidative stress
- Neuroinflammation
- NMDA receptors




Figure 1.G Alzheimer's hypothesis

Mechanism of Action

Nitrogen heterocyclic compounds act through several mechanisms.

1. Acetylcholinesterase Inhibition
Prevents breakdown of acetylcholine and improves memory.
2. Antioxidant Activity
Scavenges free radicals and protects neurons.



3. Anti-Amyloid Activity

Prevents formation of amyloid plaques.

5. Metal Chelation

Removes toxic metal ions involved in neurodegeneration.

6. Neuroprotection

Protects neuronal cells from oxidative and inflammatory damage.

Drug Design Strategies

Drug design is an important step in the development of multi-target compounds.

Rational Drug Design

Uses molecular information and computational methods to develop effective compounds.

Molecular Hybridization

Combines two pharmacophores into a single molecule.

Structure-Activity Relationship

Studies the relationship between chemical structure and biological activity.

Computer-Aided Drug Design

Uses molecular docking and simulation studies.

Synthesis of Nitrogen Heterocycles

Nitrogen heterocyclic compounds can be synthesized using various organic reactions.

Common Synthetic Methods Cyclization Reactions Formation of ring structures. Condensation Reactions

Combination of smaller molecules. Oxidation and Reduction Reactions Used for structural modifications.

Microwave-Assisted Synthesis

Provides faster reaction rates and better yields.

General Procedure

1. Selection of starting materials
2. Reaction under controlled conditions
3. Purification of products
4. Characterization of synthesized compounds

Characterization Methods

Characterization confirms the structure and purity of synthesized compounds.

IR Spectroscopy

Identifies functional groups.

Nuclear Magnetic Resonance Spectroscopy

Determines molecular structure.

Mass Spectrometry

Measures molecular weight.

UV-Visible Spectroscopy

Studies electronic transitions. Thin Layer Chromatography Checks purity of compounds. Biological Evaluation

Biological evaluation is performed to determine pharmacological activity.

In Vitro Studies

Acetylcholinesterase Inhibition Assay

Measures inhibitory activity against acetylcholinesterase.

Antioxidant Assay

Determines free radical scavenging ability.



Cytotoxicity Studies Evaluates safety profile. In Vivo Studies
Animal models are used to study memory improvement and neuroprotective activity.

Pharmacological Activities

Nitrogen heterocycles exhibit several pharmacological activities.

Antioxidant Activity

Protects cells from oxidative stress.

Anti-Inflammatory Activity

Reduces inflammation in neuronal tissues.

Neuroprotective Activity

Prevents neuronal degeneration.

Cholinesterase Inhibition

Enhances acetylcholine concentration in the brain.

Anti-Amyloid Activity Prevents plaque formation. Advantages

- Multi-target activity
- Better therapeutic outcome
- Reduced adverse effects
- Enhanced brain penetration
- Improved patient compliance
- Broad pharmacological profile

Limitations

Despite promising activity, some limitations exist.

- Complex synthesis procedures
- High research cost
- Limited clinical data
- Possible toxicity
- Difficulty in optimization

Future Scope

Future research may focus on:

- Development of safer compounds
- Use of artificial intelligence in drug design
- Clinical trials of new heterocyclic molecules
- Development of targeted drug delivery systems
- Combination therapy approaches

Nitrogen heterocyclic compounds have great potential for future Alzheimer's disease therapy.

Result and Discussion

The reviewed nitrogen heterocyclic compounds showed promising anti-Alzheimer activity through multi-target mechanisms. Quinoline and piperazine derivatives demonstrated strong cholinesterase inhibition, while indole derivatives showed potent antioxidant and neuroprotective effects. Imidazole and pyridine compounds exhibited good metal-chelating properties.

The presence of nitrogen atoms improved:

Drug binding affinity Lipophilicity

Blood-brain barrier penetration Pharmacological activity

The multi-target approach may provide better therapeutic outcomes compared to conventional single-target drugs.



II. CONCLUSION

Alzheimer's disease is a serious neurodegenerative disorder affecting millions of people worldwide. Current therapies provide only symptomatic relief and fail to stop disease progression completely.

Multi-target-directed nitrogen heterocycles represent an important area of modern medicinal chemistry. Their ability to act on multiple disease pathways such as oxidative stress, cholinesterase inhibition, amyloid aggregation, and neuroinflammation makes them promising therapeutic agents.

Continuous research in synthesis, characterization, and biological evaluation may lead to the development of safer and more effective anti-Alzheimer drugs in the future.

REFERENCES

1. Rang, H. P., Dale, M. M., Ritter, J. M., and Flower, R. J. Pharmacology. Elsevier Publications.
2. Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry.
3. Foye's Principles of Medicinal Chemistry. Lippincott Williams and Wilkins.
4. Patrick, G. L. An Introduction to Medicinal Chemistry. Oxford University Press.
5. Katzung, B. G. Basic and Clinical Pharmacology. McGraw Hill Education.
6. Goodman and Gilman's The Pharmacological Basis of Therapeutics.
7. Silverman, R. B. The Organic Chemistry of Drug Design and Drug Action.
8. Clayden, J., Greeves, N., and Warren, S. Organic Chemistry. Oxford University Press.
9. Joule, J. A., and Mills, K. Heterocyclic Chemistry. Wiley Publications.
10. Sharma, P. D. Heterocyclic Chemistry. Narosa Publishing House.
11. Stryer, L. Biochemistry. W. H. Freeman and Company.
12. Alberts, B. Molecular Biology of the Cell. Garland Science.
13. Kumar, V., Abbas, A. K., and Aster, J. C. Robbins Basic Pathology.
14. Brunton, L. L. Goodman and Gilman's Manual of Pharmacology and Therapeutics.
15. Tripathi, K. D. Essentials of Medical Pharmacology.
16. Indian Journal of Pharmaceutical Sciences.
17. European Journal of Medicinal Chemistry.
18. Journal of Medicinal Chemistry.
19. Bioorganic and Medicinal Chemistry Letters.
20. Current Neuropharmacology Journal.
21. CNS and Neurological Disorders Drug Targets Journal.
22. International Journal of Biological Macromolecules.
23. Journal of Enzyme Inhibition and Medicinal Chemistry.
24. Neurochemistry International Journal.
25. Alzheimer's and Dementia Journal.
26. Asian Journal of Pharmaceutical and Clinical Research.
27. International Journal of Pharmaceutical Research.
28. Journal of Chemical and Pharmaceutical Research.
29. Advances in Heterocyclic Chemistry.
30. Drug Discovery Today Journal.
31. Journal of Alzheimer's Disease.
32. Molecular Neurobiology Journal.
33. Journal of Pharmacy and Pharmacology.
34. International Journal of Medicinal Chemistry.
35. Research articles related to multi-target-directed ligands for Alzheimer's disease.



36. I. Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., et al (2021). Alzheimer's disease. *The Lancet*, 397(10284), 1577-1590. Volume - 2 Issue - 3 Page 7 of 8 Clinical and Medical Engineering Live Copyright © Christina Rahm
37. Khan, F. Z., Mostaid, M. S., Apu, M. N. H. (2022). Molecular signaling pathway targeted therapeutic potential of thymoquinone in Alzheimer's disease. *Heliyon*, 8(7).
38. Alzheimer's Association. (2016). 2016 Alzheimer's disease facts and figures. *Alzheimer's Dementia*, 12(4), 459-509.
39. Morello, M., Landel, V., Lacassagne, E., Baranger, K., Annweiler, C., et al (2018). Vitamin D improves neurogenesis and cognition in a mouse model of Alzheimer's disease. *Molecular neurobiology*, 55, 6463-6479.
40. Ryan, S. M., Nolan, Y. M. (2016). Neuroinflammation negatively affects adult hippocampal neurogenesis and cognition: can exercise compensate? *Neuroscience Biobehavioral Reviews*, 61, 121-131.
41. Bakulski, K. M., Seo, Y. A., Hickman, R. C., Brandt, D., Vadari, H. S., et al (2020). Heavy metals exposure and Alzheimer's disease and related dementias. *Journal of Alzheimer's Disease*, 76(4), 1215-1242.
42. Bailey, D. M., Marley, C. J., Brugniaux, J. V., Hodson, D., New, K. J., et al (2013). Elevated aerobic fitness sustained throughout the adult lifespan is associated with improved cerebral hemodynamics. *Stroke*, 44(11), 3235-3238.
43. Barnes, J. N. (2015). Exercise, cognitive function, and aging. *Advances in physiology education*, 39(2), 55-62.
44. Nelson, M. E., Rejeski, W. J., Blair, S. N., Duncan, P. W., Judge, J. O., et al (2007). Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. *Circulation*, 116(9), 1094.
45. Buchman, A. S., Boyle, P. A., Yu, L., Shah, R. C., Wilson, R. S., et al (2012). Total daily physical activity and the risk of AD and cognitive decline in older adults. *Neurology*, 78(17), 1323-1329.
46. Duzel, E., van Praag, H., Sendtner, M. (2016). Can physical exercise in old age improve memory and hippocampal function? *Brain*, 139(3), 662-673.
47. Ströhle, A., Schmidt, D. K., Schultz, F., Fricke, N., Staden, T., et al (2015). Drug and exercise treatment of Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis of effects on cognition in randomized controlled trials. *The American Journal of Geriatric Psychiatry*, 23(12), 1234-1249. <https://www.sciencedirect.com/science/article/abs/pii/S1064748115002134>
48. Vincent, G. K. (2010). The next four decades: The older population in the United States: 2010 to 2050 (No. 1138). US Department of Commerce, Economics and Statistics Administration, US Census Bureau.
49. Farina, N., Rusted, J., Tabet, N. (2014). The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review. *International Psychogeriatrics*, 26(1), 9-18.
50. Forbes, D., Forbes, S. C., Blake, C. M., Thiessen, E. J., Forbes, S. et al (2015). Exercise programs for people with dementia. *Cochrane database of systematic reviews*, (4).
51. Sacco, G., Caillaud, C., Ben Sadoun, G., Robert, P., David, R., Citation: Rahm, C. (2024). Literature Review on Alzheimer's Disease. *Clin Med Eng Live*, 2(3), 1-8. et al (2016). Exercise plus cognitive performance over and above exercise alone in subjects with mild cognitive impairment. *Journal of Alzheimer's Disease*, 50(1), 19-25.
52. Chainoglou, E., Hadjipavlou-Litina, D. (2020). Curcumin in health and diseases: Alzheimer's disease and curcumin analogues, derivatives, and hybrids. *International journal of molecular sciences*, 21(6), 1975.
53. Sattler, C., Erickson, K. I., Toro, P., Schröder, J. (2011). Physical fitness as a protective factor for cognitive impairment in a prospective population-based study in Germany. *Journal of Alzheimer's Disease*, 26(4), 709-718.
54. YY Szeto, J., JG Lewis, S. (2016). Current treatment options for Alzheimer's disease and Parkinson's disease dementia. *Current neuropharmacology*, 14(4), 326-338.
55. Barnes, D. E., Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer's disease prevalence. *The Lancet Neurology*, 10(9), 819-828.
56. Young, J., Angevaren, M., Rusted, J., Tabet, N. (2015). Aerobic exercise to improve cognitive function in older people without known cognitive impairment. *Cochrane Database of Systematic Reviews*, (4).



57. Norton, S., Matthews, F. E., Barnes, D. E., Yaffe, K., Brayne, C. et al (2014). Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. *The Lancet Neurology*, 13(8), 788-794.
58. Hamer, M., Chida, Y. (2009). Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. *Psychological medicine*, 39(1), 3-11.
59. Rolland, Y., Pillard, F., Klapouszczak, A., Reynish, E., Thomas, D., et al (2007). Exercise program for nursing home residents with Alzheimer's disease: A 1-year randomized, controlled trial. *Journal of the American Geriatrics Society*, 55(2), 158-165.
60. Kumar, A., Singh, A. (2015). A review on Alzheimer's disease pathophysiology and its management: an update. *Pharmacological reports*, 67(2), 195-203.
61. Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., et al (2006). Mild cognitive impairment. *The lancet*, 367(9518), 1262-1270.
62. Hoffmann, K., Sobol, N. A., Frederiksen, K. S., Beyer, N., Vogel, A., et al (2016). Moderate-to-high intensity physical exercise in patients with Alzheimer's disease: a randomized controlled trial. *Journal of Alzheimer's Disease*, 50(2), 443-453.
63. Smith, P. J., Blumenthal, J. A., Hoffman, B. M., Cooper, H., Strauman, T. A., et al (2010). Aerobic exercise and neurocognitive performance: a meta-analytic review of randomized controlled trials. *Psychosomatic medicine*, 72(3), 239-252.
64. Chapman, S. B., Aslan, S., Spence, J. S., DeFina, L. F., Keebler, M. W., et al (2013). Shorter term aerobic exercise improves brain, cognition, and cardiovascular fitness in aging. *Frontiers in aging neuroscience*, 5, 75.
65. Erickson, K. I., Prakash, R. S., Voss, M. W., Chaddock, L., Hu, L., et al (2009). Aerobic fitness is associated with hippocampal volume in elderly humans. *Hippocampus*, 19(10), 1030-1039.
66. Kerppers II, Hosni AP, Miri AL, Cordeiro ME, Kerppers FK, de Lima MM, et al. Therapeutic Approaches for Alzheimer's Disease: New Perspectives. *Amyloid Hist Perspect*. 2021. Available from: <https://www.intechopen.com/online-first/76042>. doi:10.5772/intechopen.97081.
67. Zvěřová M. Clinical aspects of Alzheimer's disease. *Clin Biochem*. 2019;72:3-6. doi:10.1016/j.clinbiochem.2019.04.015.
68. Crous-Bou M, Minguilón C, Gramunt N, Molinuevo JL. Review Alzheimer's disease prevention: from risk factors to early intervention. *Alzheimer's Res Ther*. 2017;9(1):1- 9.
69. Porsteinsson AP, Isaacson RS, Knox S, Sabbagh MN, Rubino I. Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. *J Prev Alzheimers Dis*. 2021;8:371-86. doi:10.14283/jpad.2021.23 116 Beera et al. *Int. J. Pharm. Res. Allied Sci.*, 2021, 10(4): 110-120
70. Hajat C, Stein E. The global burden of multiple chronic conditions: a narrative review. *Prev Med Rep*. 2018;12:284-93.
71. Winder Z, Wilcock D, Jicha GA. Diagnostic and Prognostic Laboratory Testing for Alzheimer Disease. *Clin Lab Med*. 2020;40(3):289-303.
72. Mental health, World health organization. Available from: http://www.who.int/mental_health/mhgap/en.
73. Alzheimer's Disease Facts and Figures. *Alzheimer's Dement*. Alzheimer's Assoc. 2018;14(3):367-429. Available from: <https://www.alz.org>.
74. Sadleir KR, Vassar R. Modeling genetic diversity in Alzheimer's disease. *Lab Animal*. 2019;48(3):87-8.
75. Ghara TK, Roy K. Alzheimer's Disease-An Analytical View. *IOSR-JNHS*. 2017;6(4):31- 5.
76. Tomike I, Olawande M, Ajayi P, Emmanuel P. Treatment pathways of Alzheimer in Nigeria. *Heliyon*. 2020;6(12):e05724.
77. Au R. Updates in Solving the Mystery of Alzheimer's Disease Pathology. *Int J Clin Pharmacol Pharmacother*. 2018;3(138):2. doi:10.15344/2018/2456-3501/138.
78. Santamaría TZ, Gómez PY, Galindo IF, González MG, Vázquez AO, López ML. Pharmacogenetic studies in Alzheimer disease. *Neurologia*. 2020;53(1):153.



79. Arranz AM, De Strooper B. The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications. *Lancet Neurol.* 2019;18(4):406-14.
80. Benek O, Korabecny J, Soukup O. A perspective on multi-target drugs for Alzheimers disease. *Trends Pharmacol Sci.* 2020;41(7):434-45.
81. Crismon ML. Tacrine: first drug approved for Alzheimer's disease. *Ann Pharmacother.* 1994;28(6):744-51.
82. Bastin C, Delhaye E, Moulin C, Barbeau EJ. Novelty processing and memory impairment in Alzheimer's disease: A review. *Neurosci Biobehav Rev.* 2019;100:237- 49.
83. Bamford RA, Widagdo J, Takamura N, Eve M, Anggono V, Oguro-Ando A. The interaction between contactin and amyloid precursor protein and its role in Alzheimer's disease. *Neuroscience.* 2020;424:184 202.
84. Fish PV, Steadman D, Bayle ED, Whiting P. New approaches for the treatment of Alzheimer's disease. *Bioorg Med Chem Lett.* 2019;29(2):125-33.
85. Muralidar S, Ambi SV, Sekaran S, Thirumalai D, Palaniappan B. Role of tau protein in Alzheimer's disease: The prime pathological player. *Int J Bio Macro.* 2020;163(1):1599-617.
86. Soldan A, Pettigrew C, Albert M. Cognitive reserve from the perspective of preclinical Alzheimer disease: 2020 update. *Clin Geriatr Med.* 2020;36(2):247-63.
87. Baazaoui N, Iqbal K. A novel therapeutic approach to treat Alzheimer's disease by neurotrophic support during the period of synaptic compensation. *J Alzheimers Dis.* 2018;62(3):1211-8. doi:10.3233/JAD 170839
88. McEntee WJ, Crook TH. Glutamate: its role in learning, memory, and the aging brain. *Psychopharmacology.* 1993;111(4):391-401. doi:10.1007/BF02253527.
89. Havekes R, Heckman PR, Wams EJ, Stasiukonyte N, Meerlo P, Eisel UL. Alzheimer's disease pathogenesis: The role of disturbed sleep in attenuated brain plasticity and neurodegenerative processes. *Cell Signal.* 2019;64:109420.
90. Sestito S, Daniele S, Pietrobono D, Citi V, Bellusci L, Chiellini G, et al. Memantine prodrug as a new agent for Alzheimer's Disease. *Sci Rep.* 2019;9(1):4612.
91. Bilal M, Barani M, Sabir F, Rahdar A, Kyzas GZ. Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview. *NanoImpact.* 2020:100251.
92. Pearson HA, Peers C. Physiological roles for amyloid β peptides. *J Physiol.* 2006;575(1):5-10.
93. Majdi A, Sadigh-Eteghad S, Aghsan SR, Farajdokht F, Vatandoust SM, Namvaran A, et al. Amyloid- β , tau, and the cholinergic system in Alzheimer's disease: Seeking direction in a tangle of clues. *RevNeurosci.* 2020;31(4):391-413. doi:10.1515/revneuro-2019-0089.
94. Tran L, Ha-Duong T. Exploring the Alzheimer amyloid- β peptide conformational ensemble: A review of molecular dynamics approaches. *Peptides.* 2015;69:86-91.
95. Kurz A, Perneckzy R. Novel insights for the treatment of Alzheimer's disease. *Prog Neuro psychopharmacol Biol Psychiatry.* 2011;35(2):373-9.
96. Dal Prà I, Chiarini A, Gui L, Chakravarthy B, Pacchiana R, Gardenal E, et al. Do astrocytes collaborate with neurons in spreading the "infectious" A β and Tau drivers of Alzheimer's disease?. *Neuroscientist.* 2015;21(1):9-29. 117 Beera et al. *Int. J. Pharm. Res. Allied Sci.,* 2021, 10(4): 110-120
97. Kumar A, Singh A. A review on Alzheimer's disease pathophysiology and its management: an update. *Pharmacol Rep.* 2015;67(2):195-203.
98. Rygiel K. Novel strategies for Alzheimer's disease treatment: An overview of anti- amyloid beta monoclonal antibodies. *Indian J Pharmacol.* 2016;48(6):629-36.
99. News. ALZFORUM networking cure. Roche Pulls Plug on Two Phase 3 Trials of Crenezumab. 31 Jan 2019. Available from: [https://www.alzforum.org/news/research- news/roche-pulls-plug-two-phase-3-trials-crenezumab](https://www.alzforum.org/news/research-news/roche-pulls-plug-two-phase-3-trials-crenezumab)
100. Servick K. Another major drug candidate targeting the brain plaques of Alzheimer's disease has failed. What's left? AAAS. *Science. Brain Behav Health.* 2019. doi:10.1126/science. aax4236



101. Šimić G, BabićLeko M, Wray S, Harrington C, Delalle I, Jovanov-Milošević N, et al. Tau protein hyperphosphorylation and aggregation in Alzheimer's disease and other tauopathies, and possible neuroprotective strategies. *Biomolecules*. 2016;6(1):6. doi:10.3390/biom6010006.
102. Noori T, Dehpour AR, Sureda A, Sobarzo-Sanchez E, Shirooie S. Role of natural products for the treatment of Alzheimer's disease. *Eur J Pharmacol*. 2021;898:173974.
103. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for prevention and treatment of Alzheimer's disease. *Biomed Res Int*. 2016;2016. doi:10.1155/2016/2589276.
104. Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer's disease. *Nat Rev Neurol*. 2018;14(7):399-415. doi:10.1038/s41582-018-0013-z.
105. Vasefi M, Ghabolian-Zare E, Abedelwahab H, Osu A. Environmental toxins and Alzheimer's disease progression. *Neurochem Int*. 2020;141(1):104852.
106. Wang Z, Shen L, Wang Y, Huang S. Interated analysis of miRNA and mRNA expression in the blood of patients with Alzheimer's disease. *Mol Med Rep*. 2020;22(2):1053-62.
107. Hampel H, Mesulam MM, Cuello AC, Farlow MR, Giacobini E, Grossberg GT, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. *Brain*. 2018;141(7):1917-33. targets
108. García-Osta A, Cuadrado-Tejedor M, García-Barroso C, Oyarzabal J, Franco R. Phosphodiesterases as therapeutic for doi:10.1021/cn3000907. *Alzheimer's disease*. *ACS Chem Neurosci*. 2012;3(11):832-44.
109. Guzman-Martinez L, Maccioni RB, Farias GA, Fuentes P, Navarrete LP. Biomarkers for Alzheimer's disease. *Curr Alzheimer Res*. 2019;16(6):518-28.
110. Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, et al. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. *J Neurochem*. 2008;106(1):392-404.
111. Mayeux R, Sano M. Treatment of Alzheimer's disease. *N Engl J Med*. 1999;341(22):1670-9.
112. Chakravorty A, Jetto CT, Manjithaya R. Dysfunctional mitochondria and mitophagy as drivers of Alzheimer's disease pathogenesis. *Front Aging Neurosci*. 2019;11:311. doi:10.3389/fnagi.2019.00311
113. Delrieu J, Ousset PJ, Caillaud C, Vellas B. 'Clinical trials in Alzheimer's disease: Immunotherapy approaches. *J Neurochem*. 2011; 120(1):186-93.
114. Duthey B. Priority Medicines for Europe and the World" A public health approach to innovation. *WHO Backgr Pap*. 2013;6.
115. Cummings J, Lee G, Ritter A, Zhong K. Alzheimer's disease drug development pipeline: 2018. *Alzheimers Dement*. 2018;4(1):195-214.
116. ALZ Forum, Therapeutics, (internet)AD <https://www.alzforum.org/therapeutics>. target/ therapy types. Available from:
117. Tatiparti K, Sau S, Rauf MA, Iyer AK. Smart treatment strategies for alleviating tauopathy and neuroinflammation to improve clinical outcomes in Alzheimer's disease. *Drug Discov Today*. 2020;25(12):2110-29.
118. Ankarcrona M, Winblad B, Monteiro C, Fearn C, Powers ET, Johansson J, et al. Current and future treatment of amyloid diseases. *J Intern Med*. 2016;280(2):177- 202.
119. Huang LK, Chao SP, Hu CJ. Clinical trials of new drugs for Alzheimer disease. *J Biomed Sci*. 2020;27(1):1-3. doi:10.1186/s12929-019-0609-7.
120. Zeng Q, Siu W, Li L, Jin YU, Liang S, Cao M, et al. Autophagy in Alzheimer's disease and promising modulatory effects of herbal medicine. *Exp Gerontol*. 2019;119:100-10.
121. Adewusi EA, Steenkamp V. Medicinal plants and their derivatives with amyloid-beta inhibitory activity as potential targets for drug discovery. *Asian Pac J Trop Dis*. 2015;1808(15):60810-6. 118 Beera et al. *Int. J. Pharm. Res. Allied Sci.*, 2021, 10(4): 110-120
122. Fang J, Wang L, Wu T, Yang C, Gao L, Cai H, et al. Network pharmacology- based study on the mechanism of action for herbal medicines in Alzheimer treatment. *J Ethnopharmacol*. 2017;196:281-92.



123. Liu H, Ye M, Guo H. An updated review of randomized clinical trials testing the improvement of cognitive function of Ginkgo biloba extract in healthy people and Alzheimer's patients. *Front Pharmacol.* 2020;10:1688.
124. Janben IM, Sturtz S, Skipka G, Zentner A, Garrido MV, Busse R. Ginkgo biloba in Alzheimer's disease: A Systematic review. *Wien Med Wochenschr.* 2010;160(21):539-46.
125. Ringman JM, Frautschy SA, Cole GM, Masterman DL, Cummings JL. A potential role of the curry spice curcumin in Alzheimer's disease. *Curr Alzheimer Res.* 2005;2(2):131-6.
126. Li Y, Guan S, Liu C, Chen X, Zhu Y, Xie Y, et al. Neuroprotective effects of Coptis chinensis Franch polysaccharide on amyloid-beta (A β)-induced toxicity in a transgenic *Caenorhabditis elegans* model of Alzheimer's disease (AD). *Int J Biol Macromol.* 2018;113:991-5.
127. Zhang Y, Noh K, Song W. Chinese herbal medicines on cognitive function and activity of daily living in senior adults with Alzheimer's disease: a systematic review and meta-analysis. *Integr Med Res.* 2019;8(2):92-100.
128. Oh JJ, Kim SJ. Inhibitory Effect of the root of *Polygala tenuifolia* on Bradykinin and COX 2-Mediated Pain and Inflammatory Activity. *Trop J Pharm Res.* 2013;12(5):755-9.
129. Adalier N, Parker H. Vitamin E, turmeric and saffron in treatment of Alzheimer's disease. *Antioxidants.* 2016;5(4):40.
130. Zhang XZ, Qian SS, Zhang YJ, Wang RQ. *Salvia miltiorrhiza*: A source for anti- Alzheimer's disease drugs. *Pharm Biol.* 2016;54(1):18-24.
131. Kuboyama T, Tohda C, Komatsu K. Effects of Ashwagandha (roots of *Withania somnifera*) on neurodegenerative diseases. *Biol Pharm Bull.* 2014;37(6):892-7.
132. Satalangka C, Wattanathorn J, Muchimapura S, Thukham-mee W. *Moringaoleifera* mitigates memory impairment and neurodegeneration in animal model of age-related dementia. *Oxid Med Cell Longev.* 2013;695936.
133. Chaudhari KS, Tiwari NR, Tiwari RR, Sharma RS. Neurocognitive effect of nootropic drug Brahmi (*Bacopamonnieri*) in Alzheimer's disease. *Ann Neurosci.* 2017;24(2):111-22.
134. Madhavadas S, Subramanian S. Cognition enhancing effect of the aqueous extract of *Cinnamomum zeylanicum* on non-transgenic Alzheimer's disease rat model: Biochemical, histological, and behavioural studies. *Nutr Neurosci.* 2017;20(9):526-37.
135. Huang S, Mao J, Ding K, Zhou Y, Zeng X, Yang W, et al. Polysaccharides from *Ganoderma lucidum* promote cognitive function and neural progenitor proliferation in mouse model of Alzheimer's disease. *Stem Cell Rep.* 2017;8(1):84-94.
136. Aducanumab. therapeutics. Databases. ALZforum Networking for cure. updated 2019. Available from: <https://www.alzforum.org/therapeutics/aducanumab>
137. Viglietta V, O'Gorman J, Williams L, Tian Y, Sandrock A, Doody R, et al. Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer's Disease: Phase 3 Study Design (S1.003). *Neurology.* 2016;86(16 Supplement) S1.003.
138. Howard R, Liu KY. Questions EMERGE as Biogen claims aducanumab turnaround. *Nat Rev Neurol.* 2020;16(2):63-4. doi:10.1038/s41582-019-0295-9.
139. Joseph A. A new Alzheimer's therapy is approved in China, delivering a surprise for the field but also questions. 2019. Available from: <https://www.statnews.com/2019/11/04/a-new-alzheimers-therapy-is-approved-in-china-delivering-a-surprise-for-the-field-but-also-questions/>
140. Servick K, Normile D. Alzheimer's experts greet China's surprise approval of a drug for brain disease with hope and caution. (*Asia/PacificHealth.*). *sciencemag.org.* 2019. doi:10.1126/science.aba1117
141. Thaïss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. *Nature.* 2016;535(7610):65-74.
142. Blander JM, Longman RS, Iliev ID, Sonnenberg GF, Artis D. Regulation of inflammation by microbiota interactions with the host. *Nat Immunol.* 2017;18(8):851-60.



143. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, et al. Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids- shaped neuroinflammation to inhibit Alzheimer's disease progression. *Cell Res.* 2019;29(10):787-803. 119 Beera et al. *Int. J. Pharm. Res. Allied Sci.*, 2021, 10(4): 110-120
144. GV-971, Therapeutics. Database. ALZforum networking for a cure. Available from: <https://www.alzforum.org/therapeutics/gv-971>.
145. Osman AS, Gad MH, Hareedy AA, Mishriki AA, Rasheed EA. Sitagliptin attenuates cognitive impairment in the rat model of Aluminuminduced Alzheimer's disease. *J Adv Pharm Educ Res.* 2019;9(3):53-61.
146. Xiao S, Chan P, Wang T, Hong Z, Wang S, Kuang W, et al. A 36-week multicenter, randomized, double blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to moderate Alzheimer's dementia. *Alzheimers Res Ther.* 2021;13(1):62.
147. Plascencia-Villa G, Perry G. Status and future directions of clinical trials in Alzheimer's disease. *Int Rev Neurobiol.* 2020;154:3-50.

